Trial · NCT00357396
Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors
NCT00357396, Phase 2, Completed, Memorial Sloan Kettering Cancer Center; results first posted 2015-11-25
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors. Trials, record NCT00357396. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00357396
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors
- NCT number
- NCT00357396
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 10 participants, actual
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Conditions
- Sarcoma
- Interventions
graft versus host disease prophylaxis/therapy, busulfan, melphalan, thiotepa, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- First posted
- 2006-07-27
- Last updated
- 2015-11-25
- Results first posted
- 2015-11-25
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Objective Response | 2 years |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Overall Objective Response | 2 years | participants | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Objective Response | Patients With HIGH RISK EWING'S SARCOMA FAMILY TUMOR | Very Good Partial Response (VGPR) | 4 | participants | |
| Overall Objective Response | Patients With HIGH RISK EWING'S SARCOMA FAMILY TUMOR | Complete Response (CR) | 1 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Patients With HIGH RISK EWING'S SARCOMA FAMILY TUMOR | 6 | |
| Overall Study | STARTED | Related Donors | 4 | |
| Overall Study | COMPLETED | Patients With HIGH RISK EWING'S SARCOMA FAMILY TUMOR | 5 | |
| Overall Study | COMPLETED | Related Donors | 4 | |
| Overall Study | NOT COMPLETED | Patients With HIGH RISK EWING'S SARCOMA FAMILY TUMOR | 1 | |
| Overall Study | NOT COMPLETED | Related Donors | 0 |
Source ClinicalTrials.gov
Adverse events82
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ALT, SGPT | Blood and lymphatic system disorders | Patients With HIGH RISK EWING'S SARCOMA FAMILY TUMOR | 6 | 6 | 6 |
| other | ALT, SGPT | Blood and lymphatic system disorders | Related Donors | 0 | 4 | 0 |
| other | AST, SGOT | Blood and lymphatic system disorders | Patients With HIGH RISK EWING'S SARCOMA FAMILY TUMOR | 5 | 6 | 5 |
| other | AST, SGOT | Blood and lymphatic system disorders | Related Donors | 0 | 4 | 0 |
| other | Albumin, low (hypoalbuminemia) | Metabolism and nutrition disorders | Patients With HIGH RISK EWING'S SARCOMA FAMILY TUMOR | 4 | 6 | 4 |
| other | Albumin, low (hypoalbuminemia) | Metabolism and nutrition disorders | Related Donors | 0 | 4 | 0 |
| other | Alkaline phosphatase | Metabolism and nutrition disorders | Patients With HIGH RISK EWING'S SARCOMA FAMILY TUMOR | 5 | 6 | 5 |
| other | Alkaline phosphatase | Metabolism and nutrition disorders | Related Donors | 0 | 4 | 0 |
| other | Amylase | Metabolism and nutrition disorders | Patients With HIGH RISK EWING'S SARCOMA FAMILY TUMOR | 1 | 6 | 1 |
| other | Amylase | Metabolism and nutrition disorders | Related Donors | 0 | 4 | 0 |
1 to 10 of 82Source ClinicalTrials.gov
See all 82 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Patients With HIGH RISK EWING'S SARCOMA FAMILY TUMOR | ||
| Total, all-cause mortality | Related Donors | ||
| Total, other adverse events | Patients With HIGH RISK EWING'S SARCOMA FAMILY TUMOR | 6 | 6 |
| Total, other adverse events | Related Donors | 0 | 4 |
| Total, serious adverse events | Patients With HIGH RISK EWING'S SARCOMA FAMILY TUMOR | 4 | 6 |
| Total, serious adverse events | Related Donors | 0 | 4 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Patients With HIGH RISK EWING'S SARCOMA FAMILY TUMOR vs Related Donors: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00357396
GET https://conductscience.org/api/trials/v1/NCT00357396/events?page=2